JUBLPHARMA - Technical Analysis with Chart Patterns & Indicators

Last Updated Time : 05 Nov 25, 7:43 am

Technical Rating: 3.1

📉 JUBLPHARMA is consolidating near its 50 DMA with neutral momentum indicators and mixed volume trends, suggesting caution for short-term entry.

📊 Technical Analysis

• Trend: The stock is consolidating between its 50 DMA (₹1,103) and 200 DMA (₹1,057), showing indecision in trend direction.
• Moving Averages: Price is above both key averages, indicating mild bullish sentiment but not a confirmed uptrend.
• RSI (48.8): Neutral zone, suggesting balanced momentum with no strong buy/sell signal.
• MACD (6.89): Positive crossover, indicating early bullish momentum but not yet strong.
• Bollinger Bands: Price is trading below the middle band, suggesting weakness and potential volatility

  tick.dailybulls.in

  .

• Volume: Current volume (5.70L) is above 1-week average (2.75L), indicating recent accumulation interest

  tick.dailybulls.in

  .

Sources

tick.dailybulls.in

+2

🎯 Entry & Exit Zones

• Support Zone: ₹1,050 – ₹1,070 (200 DMA and recent base)
• Resistance Zone: ₹1,190 – ₹1,210 (recent swing highs)
• Optimal Entry: ₹1,070 – ₹1,090 (if RSI rises above 50 and MACD remains positive)
• Exit Target: ₹1,200 – ₹1,220 (short-term resistance zone)

✅ Positive

• EPS of ₹1.15 and dividend yield of 0.44% offer modest income potential.
• Low debt-to-equity ratio (0.02) reflects strong financial discipline.
• DII holding increased by 1.01%, showing domestic institutional confidence.

⚠️ Limitation

• ROCE (2.91%) and ROE (1.04%) are low, indicating weak capital efficiency.
• MACD and RSI are neutral, offering no strong directional cues.
• Missing P/E and PEG ratios limit valuation clarity.

📉 Company Negative News

• Quarterly PAT dropped from ₹4.10 Cr. to -₹48.0 Cr., a 436% decline.
• FII holding decreased by 0.84%, indicating reduced foreign investor interest.

📈 Company Positive News

• Stock has gained 72.3% over the past year, reflecting long-term investor interest.
• MACD crossover and volume spike suggest potential accumulation.

🧪 Industry

• Industry P/E is 33.1, suggesting JUBLPHARMA may be undervalued if earnings stabilize.
• Pharmaceutical sector is defensive and driven by innovation, regulatory approvals, and global demand.

🧾 Conclusion

• JUBLPHARMA is currently consolidating with neutral technical indicators and mixed sentiment.
• Short-term traders should wait for RSI to cross 50 and MACD to strengthen before entering.
• Long-term investors may consider accumulating near ₹1,070 with a target of ₹1,220, maintaining stop-loss below ₹1,050.